US · HCM
HUTCHMED (China) Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Hong Kong
- Website
- hutch-med.com
Price · as of 2024-12-31
$13.30
Market cap 2.59B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $37.08 | +178.8% |
| Intrinsic Value(DCF) | $8.91 | -33.01% |
| Graham-Dodd Method(GD) | $5.53 | -58.44% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.24 | $0.00 | |||
| 2011 | $0.66 | $0.21 | |||
| 2012 | $0.70 | $0.85 | |||
| 2013 | $1.13 | $0.00 | |||
| 2014 | $1.14 | $5.30 | |||
| 2015 | $13.50 | $47.70 | $1,718.56 | $1.10 | $7.17 |
| 2016 | $14.16 | $33.10 | $2,021.90 | $2.01 | $2.78 |
| 2017 | $36.60 | $40.13 | $229.27 | $2.63 | $0.00 |
| 2018 | $26.90 | $31.35 | $1.32 | $0.09 | $1.45 |
| 2019 | $25.00 | $31.40 | $0.30 | $0.00 | $0.00 |
| 2020 | $28.85 | $35.21 | $1.55 | $0.00 | $0.00 |
| 2021 | $17.09 | $29.15 | $3.74 | $0.00 | $0.00 |
| 2022 | $14.20 | $21.95 | $1.23 | $0.00 | $0.00 |
| 2023 | $14.87 | $55.31 | $2,611.33 | $7.25 | $59.62 |
| 2024 | $16.53 | $37.08 | $112.79 | $5.53 | $0.00 |
AI valuation
Our deep-learning model estimates HUTCHMED (China) Limited's (HCM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $37.08
- Current price
- $13.30
- AI upside
- +178.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.91
-33.01% upside
Graham-Dodd
$5.53
-58.44% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HCM | HUTCHMED (China) Limited | $13.30 | 2.59B | +179% | -33% | -58% | — | 74.95 | 3.72 | 4.49 | 147.56 | — | 3.74 | 44.64% | -6.94% | 5.99% | 5.06% | 131.28% | 2.95% | 0.12 | -15.22 | 2.83 | 2.67 | -4.55 | -6333.00% | -2480.00% | -10934.00% | -0.62% | 0.00 | 62.24% | 0.00% | 0.00% | 1.28% | -47.63 | -119.38 | 3.30 | 3.49 |
| ADPT | Adaptive Biotechnologies … | $16.02 | 2.46B | +132% | +239% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| CDTX | Cidara Therapeutics, Inc. | $221.38 | 5.61B | -67% | -96% | — | +934% | -0.88 | 0.92 | 117.83 | 0.20 | -0.22 | 0.92 | -6557.49% | -13811.92% | -13319.76% | -218.99% | 567.59% | -120.52% | 0.02 | — | 4.25 | 3.86 | 1.06 | 40952.00% | -9800.00% | 67021.00% | -117.59% | -3.56 | 569.40% | 0.00% | 0.00% | 103.41% | 0.20 | 0.20 | -28.25 | -4.03 |
| CPRX | Catalyst Pharmaceuticals,… | $23.08 | 2.84B | +180% | +200% | -28% | +106% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| KNSA | Kiniksa Pharmaceuticals, … | $44.49 | 3.3B | +56% | +8,673% | -74% | +17% | -79.02 | 6.01 | 5.04 | 33.27 | — | 6.18 | 54.63% | 11.40% | 8.71% | -8.59% | 27.89% | -6.43% | 0.02 | — | 3.79 | 3.09 | -1.73 | -22500.00% | 6009.00% | 0.00% | 0.74% | 0.18 | 13.82% | 0.00% | 0.00% | 0.23% | 38.96 | 118.40 | 4.44 | 11.43 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| PRGO | Perrigo Company plc | $13.22 | 1.82B | -63% | -63% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
- CEO
- Chig Fung Cheng
- Employees
- 1.81K
- Beta
- 0.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.91 ÷ $13.30) − 1 = -33.01% (DCF, example).